$8.04
2.88% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US14070B1017
Symbol
CAPR

Capricor Therapeutics, Inc. Stock price

$8.04
+0.66 8.87% 1M
-7.01 46.58% 6M
-5.76 41.74% YTD
+4.12 105.10% 1Y
+3.04 60.80% 3Y
+2.10 35.35% 5Y
-34.86 81.26% 10Y
+1.54 23.69% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.23 2.88%
ISIN
US14070B1017
Symbol
CAPR
Industry

Key metrics

Basic
Market capitalization
$357.2m
Enterprise Value
$215.8m
Net debt
positive
Cash
$144.8m
Shares outstanding
45.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
20.6 | 13.8
EV/Sales
12.4 | 8.3
EV/FCF
negative
P/B
2.8
Financial Health
Equity Ratio
85.3%
Return on Equity
-27.8%
ROCE
-43.6%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$17.4m | $25.9m
EBITDA
$-56.9m | $-103.1m
EBIT
$-57.3m | $-91.3m
Net Income
$-55.1m | $-44.3m
Free Cash Flow
$-47.2m
Growth (TTM | estimate)
Revenue
-36.0% | 16.3%
EBITDA
-127.6% | -470.1%
EBIT
-119.0% | -367.9%
Net Income
-126.4% | -9.4%
Free Cash Flow
-41.5%
Margin (TTM | estimate)
Gross
-
EBITDA
-327.6% | -398.3%
EBIT
-329.9%
Net
-317.1% | -171.0%
Free Cash Flow
-271.7%
More
EPS
$-1.2
FCF per Share
$-1.0
Short interest
24.4%
Employees
160
Rev per Employee
$140.0k
Show more

Is Capricor Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Capricor Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

16 Analysts have issued a Capricor Therapeutics, Inc. forecast:

15x Buy
94%
1x Hold
6%

Analyst Opinions

16 Analysts have issued a Capricor Therapeutics, Inc. forecast:

Buy
94%
Hold
6%

Financial data from Capricor Therapeutics, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
17 17
36% 36%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
25% 25%
96%
- Research and Development Expense 58 58
44% 44%
332%
-57 -57
128% 128%
-328%
- Depreciation and Amortization 0.41 0.41
65% 65%
2%
EBIT (Operating Income) EBIT -57 -57
119% 119%
-330%
Net Profit -55 -55
126% 126%
-317%

In millions USD.

Don't miss a Thing! We will send you all news about Capricor Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Capricor Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
about 12 hours ago
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Capricor To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
one day ago
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR). Shareholders who purchased shares of CAPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
Neutral
PRNewsWire
4 days ago
NEW YORK , Aug. 8, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Capricor Therapeutics, Inc. (NASDAQ: CAPR) between October 9, 2024 and July 10, 2025, both dates inclusive (the "Class Period"), of the important September 15, 2025 lead plaintiff deadline. So what: If you purchased Capricor securities during the Class Period you m...
More Capricor Therapeutics, Inc. News

Company Profile

Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

Head office United States
CEO Linda Marbán
Employees 160
Founded 1996
Website capricor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today